Novo Nordisk A/S (NVO)
Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 15.3473
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 2139726182063.5337
- FreeCF/Share 16.8361
- PFCF 28.6274
- PE 20.3242
- Debt/Assets 0.2427
- DivYield 0.0218
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Read More
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (June 2025)
Published: June 20, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Read More
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Read More
The Big 3: NVO, DIS, WHR
Published: June 13, 2025 by: Schwab Network
Sentiment: Positive
Andrew Arons joins today's Big 3 to talk about stocks he believes can make 20% moves over the next year. He sees Novo Nordisk (NVO) benefitting off a rising weight-loss drug trends, Walt Disney (DIS) excelling in its "experiences" sectors, and Whirlpool (WHR) gaining hedge fund interest as it recovers off a 52-week low.
Read More
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
Read More
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin
Published: June 12, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese.
Read More
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management.
Read More
NVO Stock Gains After Parvus Asset Management Builds Stake
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Read More
Novo Nordisk: The Time To Buy Has Come
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investors. Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market, despite revised guidance due to compounded drug impacts. NVO actively combats compounded GLP-1s via legal routes, new patient access programs like $499 Wegovy, and key formulary wins such as CVS exclusivity.
Read More
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
Read More
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Read More
Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds
Published: May 27, 2025 by: Proactive Investors
Sentiment: Neutral
A fresh physician poll has revived debate over the shifting balance of power in the weight-loss drug market. According to Deutsche Bank, the snapshot shows a marginal swing in favour of Eli Lilly and Co's (NYSE:LLY) Zepbound over Novo Nordisk's (NYSE:NVO) Wegovy.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Is Novo Nordisk Immune To President Trump's Drug Price Plans
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products and the successes achieved in developing its clinical-stage projects. So, the semaglutide franchise's total sales reached DKK 50 billion in the first quarter of 2025, an increase of 18.7% year-on-year.
Read More
Final Trade: AAPL, NVO, TLT, X
Published: May 23, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Read More
Mizuho's Jared Holz talks what is next for Novo Nordisk
Published: May 23, 2025 by: CNBC Television
Sentiment: Negative
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
3 Overlooked Dividend Growers With 10%+ Annual Dividend Increases
Published: May 22, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks can significantly amplify the compounding of your portfolio.
Read More
Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers
Published: May 22, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.
Read More
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide" Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredients PLAINSBORO, N.J. , May 22, 2025 /PRNewswire/ -- …
Read More
Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO
Published: May 22, 2025 by: Reuters
Sentiment: Neutral
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)
Published: May 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Novo Nordisk Woes Weigh on Denmark's Economy. Here's How.
Published: May 20, 2025 by: Barrons
Sentiment: Negative
Denmark's economy contracted 0.5% in the first quarter of 2025, largely due to the pharmaceutical industry.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Mr. Lars Fruergaard Jorgensen
- Employees 77406